The use of proliferative markers such as Ki‐67, Cyclin D1, PHH3, and PCNA has garnered increasing attention for their potential as prognostic and predictive tools in cancer treatment, including pancreatic cancer [38]. This evidence concerns the gene PCNA and familial pancreatic carcinoma.